313 related articles for article (PubMed ID: 11086045)
1. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
2. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
3. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
4. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
J Immunol; 2007 Oct; 179(8):5033-40. PubMed ID: 17911588
[TBL] [Abstract][Full Text] [Related]
5. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
6. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
7. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
8. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
9. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
10. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
Goldberg J; Shrikant P; Mescher MF
J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
[TBL] [Abstract][Full Text] [Related]
11. The role of T cell antagonism and original antigenic sin in genetic immunization.
Singh RA; Rodgers JR; Barry MA
J Immunol; 2002 Dec; 169(12):6779-86. PubMed ID: 12471109
[TBL] [Abstract][Full Text] [Related]
12. Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants.
Sheikh NA; Rajananthanan P; Attard GS; Morrow WJ
Vaccine; 1999 Aug; 17(23-24):2974-82. PubMed ID: 10462232
[TBL] [Abstract][Full Text] [Related]
13. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.
Basler M; Youhnovski N; Van Den Broek M; Przybylski M; Groettrup M
J Immunol; 2004 Sep; 173(6):3925-34. PubMed ID: 15356141
[TBL] [Abstract][Full Text] [Related]
14. Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal.
Boisgérault F; Rueda P; Sun CM; Hervas-Stubbs S; Rojas M; Leclerc C
J Immunol; 2005 Mar; 174(6):3432-9. PubMed ID: 15749877
[TBL] [Abstract][Full Text] [Related]
15. The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo.
Harmala LA; Ingulli EG; Curtsinger JM; Lucido MM; Schmidt CS; Weigel BJ; Blazar BR; Mescher MF; Pennell CA
J Immunol; 2002 Nov; 169(10):5622-9. PubMed ID: 12421941
[TBL] [Abstract][Full Text] [Related]
16. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice.
Sette AD; Oseroff C; Sidney J; Alexander J; Chesnut RW; Kakimi K; Guidotti LG; Chisari FV
J Immunol; 2001 Jan; 166(2):1389-97. PubMed ID: 11145724
[TBL] [Abstract][Full Text] [Related]
17. Injection of soluble antigen into the anterior chamber of the eye induces expansion and functional unresponsiveness of antigen-specific CD8+ T cells.
McKenna KC; Xu Y; Kapp JA
J Immunol; 2002 Nov; 169(10):5630-7. PubMed ID: 12421942
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
Rubinstein MP; Kadima AN; Salem ML; Nguyen CL; Gillanders WE; Cole DJ
J Immunol; 2002 Nov; 169(9):4928-35. PubMed ID: 12391205
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses.
Towne CF; York IA; Watkin LB; Lazo JS; Rock KL
J Immunol; 2007 Jun; 178(11):6923-30. PubMed ID: 17513741
[TBL] [Abstract][Full Text] [Related]
20. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.
Luketic L; Delanghe J; Sobol PT; Yang P; Frotten E; Mossman KL; Gauldie J; Bramson J; Wan Y
J Immunol; 2007 Oct; 179(8):5024-32. PubMed ID: 17911587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
